Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares Acquired by Phoenix Holdings Ltd.

Phoenix Holdings Ltd. lifted its holdings in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) by 45.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,872 shares of the biopharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Phoenix Holdings Ltd. owned about 0.08% of Vascular Biogenics worth $35,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Wedbush Securities Inc. lifted its holdings in Vascular Biogenics by 142.2% in the 3rd quarter. Wedbush Securities Inc. now owns 54,500 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 32,000 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Vascular Biogenics in the 2nd quarter worth $25,000. Virtu Financial LLC acquired a new position in Vascular Biogenics in the 2nd quarter worth $25,000. Envestnet Asset Management Inc. lifted its holdings in Vascular Biogenics by 29.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 46,097 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 10,463 shares in the last quarter. Finally, Advisor Group Holdings Inc. acquired a new position in Vascular Biogenics in the 1st quarter worth $69,000. Institutional investors and hedge funds own 6.10% of the company’s stock.

VBLT has been the subject of several research analyst reports. Zacks Investment Research raised shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Friday, August 21st. Chardan Capital reissued a “buy” rating and issued a $5.00 target price on shares of Vascular Biogenics in a research report on Thursday, August 13th. Six research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $3.40.

Shares of NASDAQ:VBLT opened at $1.19 on Friday. The company has a quick ratio of 6.41, a current ratio of 6.41 and a debt-to-equity ratio of 0.05. Vascular Biogenics Ltd. has a fifty-two week low of $0.90 and a fifty-two week high of $1.64. The firm has a 50-day simple moving average of $1.17 and a 200 day simple moving average of $1.24. The company has a market cap of $49.96 million, a PE ratio of -2.02 and a beta of 0.90.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings data on Sunday, November 15th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. Vascular Biogenics had a negative net margin of 2,987.11% and a negative return on equity of 57.70%. As a group, research analysts forecast that Vascular Biogenics Ltd. will post -0.56 EPS for the current fiscal year.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Story: Quiet Period Expirations Explained

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.